Ampio Pharmaceuticals, Inc. (NYSE: AMPE) 40.9% HIGHER; announced positive results of the OptimEyes trial for DME. The OptimEyes trial was a multiple site, randomized, placebo controlled, parallel, double masked study to evaluate the safety and efficacy of two doses of oral Optina (adjusted to body mass index-BMI) in adult patients with Diabetic Macular Edema (DME).
CTPartners Executive Search (NYSE: